NASDAQ:LAB Standard BioTools (LAB) Stock Price, News & Analysis $1.96 +0.08 (+4.26%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Standard BioTools Stock (NASDAQ:LAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Standard BioTools alerts:Sign Up Key Stats Today's Range$1.93▼$2.2650-Day Range$1.68▼$2.1852-Week Range$1.21▼$3.04Volume4.63 million shsAverage Volume2.47 million shsMarket Capitalization$727.46 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company OverviewStandard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.Read More… Banking failure dead ahead (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Standard BioTools Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks53rd Percentile Overall ScoreLAB MarketRank™: Standard BioTools scored higher than 53% of companies evaluated by MarketBeat, and ranked 585th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingStandard BioTools has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStandard BioTools has only been the subject of 1 research reports in the past 90 days.Read more about Standard BioTools' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Standard BioTools are expected to grow in the coming year, from ($0.42) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Standard BioTools is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Standard BioTools is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Standard BioTools' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.94% of the float of Standard BioTools has been sold short.Short Interest Ratio / Days to CoverStandard BioTools has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Standard BioTools has recently increased by 0.19%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStandard BioTools does not currently pay a dividend.Dividend GrowthStandard BioTools does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.94% of the float of Standard BioTools has been sold short.Short Interest Ratio / Days to CoverStandard BioTools has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Standard BioTools has recently increased by 0.19%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment0.49 News SentimentStandard BioTools has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Standard BioTools this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for LAB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added Standard BioTools to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Standard BioTools insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,662,080.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders53.10% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.74% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Standard BioTools' insider trading history. Receive LAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter. Email Address LAB Stock News HeadlinesStandard BioTools to Participate in Upcoming Investor ConferencesOctober 31 at 8:01 AM | globenewswire.comStandard BioTools Reports Third Quarter 2024 Financial ResultsOctober 30 at 4:01 PM | globenewswire.comBanking failure dead aheadIf you missed it, my emergency election broadcast is now available - but will be removed soonOctober 31, 2024 | Porter & Company (Ad)Millennium Management LLC Acquires Shares in Standard BioTools IncOctober 22, 2024 | finance.yahoo.comStandard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024October 16, 2024 | globenewswire.comIs Standard BioTools Inc. (LAB) the Best NASDAQ Stock Under $5?October 3, 2024 | msn.comShareholders in Standard BioTools (NASDAQ:LAB) are in the red if they invested three years agoSeptember 19, 2024 | finance.yahoo.comStandard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH)September 18, 2024 | markets.businessinsider.comSee More Headlines LAB Stock Analysis - Frequently Asked Questions How have LAB shares performed this year? Standard BioTools' stock was trading at $2.21 at the beginning of 2024. Since then, LAB stock has decreased by 11.3% and is now trading at $1.96. View the best growth stocks for 2024 here. How were Standard BioTools' earnings last quarter? Standard BioTools Inc. (NASDAQ:LAB) announced its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.05. The business had revenue of $44.97 million for the quarter, compared to analyst estimates of $42 million. Standard BioTools had a negative trailing twelve-month return on equity of 43.45% and a negative net margin of 87.05%. Who are Standard BioTools' major shareholders? Standard BioTools' top institutional shareholders include SG Americas Securities LLC (0.03%), Creative Planning (0.01%) and Nisa Investment Advisors LLC. Insiders that own company stock include Casdin Partners Master Fund, L and Caligan Partners Lp. View institutional ownership trends. How do I buy shares of Standard BioTools? Shares of LAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Standard BioTools own? Based on aggregate information from My MarketBeat watchlists, some other companies that Standard BioTools investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings10/30/2024Today10/31/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/26/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:LAB CUSIPN/A CIK1162194 Webwww.fluidigm.com Phone(650) 266-6000Fax650-871-7152Employees620Year FoundedN/APrice Target and Rating Average Stock Price Target$2.88 High Stock Price Target$3.25 Low Stock Price Target$2.50 Potential Upside/Downside+53.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,660,000.00 Net Margins-87.05% Pretax Margin-87.00% Return on Equity-43.45% Return on Assets-16.33% Debt Debt-to-Equity RatioN/A Current Ratio3.88 Quick Ratio3.53 Sales & Book Value Annual Sales$136.30 million Price / Sales5.34 Cash FlowN/A Price / Cash FlowN/A Book Value($1.85) per share Price / Book-1.06Miscellaneous Outstanding Shares371,154,000Free Float174,071,000Market Cap$727.46 million OptionableOptionable Beta1.58 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:LAB) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Standard BioTools With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.